PE20131107A1 - Forma de dosificacion farmaceutica que comprende 6'-fluoro-(n-metil- o n,n-dimetil)-4-fenil-4-fenil-4',9'-dihidro-3'h-espiro[ciclohexan-1,1'-pirano[3,4,b]indol]-4-amina - Google Patents

Forma de dosificacion farmaceutica que comprende 6'-fluoro-(n-metil- o n,n-dimetil)-4-fenil-4-fenil-4',9'-dihidro-3'h-espiro[ciclohexan-1,1'-pirano[3,4,b]indol]-4-amina

Info

Publication number
PE20131107A1
PE20131107A1 PE2013000192A PE2013000192A PE20131107A1 PE 20131107 A1 PE20131107 A1 PE 20131107A1 PE 2013000192 A PE2013000192 A PE 2013000192A PE 2013000192 A PE2013000192 A PE 2013000192A PE 20131107 A1 PE20131107 A1 PE 20131107A1
Authority
PE
Peru
Prior art keywords
phenyl
spyro
pyrane
cyclohexan
indol
Prior art date
Application number
PE2013000192A
Other languages
English (en)
Spanish (es)
Inventor
Marc Schiller
Nadja Gruning
Ingo Friedrich
Chris Kirby
Original Assignee
Gruenenthal Chemie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43481034&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20131107(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gruenenthal Chemie filed Critical Gruenenthal Chemie
Publication of PE20131107A1 publication Critical patent/PE20131107A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
PE2013000192A 2010-08-04 2011-08-04 Forma de dosificacion farmaceutica que comprende 6'-fluoro-(n-metil- o n,n-dimetil)-4-fenil-4-fenil-4',9'-dihidro-3'h-espiro[ciclohexan-1,1'-pirano[3,4,b]indol]-4-amina PE20131107A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10008116 2010-08-04
US201161370643P 2011-08-04 2011-08-04

Publications (1)

Publication Number Publication Date
PE20131107A1 true PE20131107A1 (es) 2013-10-17

Family

ID=43481034

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013000192A PE20131107A1 (es) 2010-08-04 2011-08-04 Forma de dosificacion farmaceutica que comprende 6'-fluoro-(n-metil- o n,n-dimetil)-4-fenil-4-fenil-4',9'-dihidro-3'h-espiro[ciclohexan-1,1'-pirano[3,4,b]indol]-4-amina

Country Status (28)

Country Link
EP (1) EP2600839B1 (sl)
JP (1) JP5792300B2 (sl)
KR (1) KR101828768B1 (sl)
CN (1) CN103179953A (sl)
AR (1) AR082560A1 (sl)
AU (1) AU2011287956B2 (sl)
BR (1) BR112013002714A2 (sl)
CA (1) CA2804878C (sl)
CL (1) CL2012003582A1 (sl)
CO (1) CO6640315A2 (sl)
CY (1) CY1119887T1 (sl)
DK (1) DK2600839T3 (sl)
EC (1) ECSP13012419A (sl)
ES (1) ES2665344T3 (sl)
HR (1) HRP20180143T1 (sl)
HU (1) HUE035543T2 (sl)
IL (1) IL223880A (sl)
LT (1) LT2600839T (sl)
MX (1) MX345068B (sl)
NZ (1) NZ604735A (sl)
PE (1) PE20131107A1 (sl)
PL (1) PL2600839T3 (sl)
PT (1) PT2600839T (sl)
RS (1) RS57027B1 (sl)
RU (1) RU2582390C2 (sl)
SI (1) SI2600839T1 (sl)
WO (1) WO2012016699A2 (sl)
ZA (1) ZA201300038B (sl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201642853A (zh) * 2015-01-23 2016-12-16 歌林達有限公司 用於治療肝功能之損傷及／或腎功能之損傷個體疼痛之西博帕多（Ｃｅｂｒａｎｏｐａｄｏｌ）
BR112018017167A2 (pt) 2016-02-29 2019-01-02 Gruenenthal Gmbh titulação de cebranopadol

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR038681A1 (es) * 2002-02-14 2005-01-26 Solvay Pharm Bv Formulacion oral de solucion solida de una sustancia activa pobremente soluble en agua
DE10252667A1 (de) * 2002-11-11 2004-05-27 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
DE102005005446A1 (de) * 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
US20070048228A1 (en) * 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE102006046745A1 (de) * 2006-09-29 2008-04-03 Grünenthal GmbH Gemischte ORL1/µ-Agonisten zur Behandlung von Schmerz
DE102007009235A1 (de) * 2007-02-22 2008-09-18 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate

Also Published As

Publication number Publication date
CA2804878A1 (en) 2012-02-09
SI2600839T1 (sl) 2018-04-30
ECSP13012419A (es) 2013-03-28
AR082560A1 (es) 2012-12-19
RU2013109134A (ru) 2014-09-10
MX345068B (es) 2017-01-16
LT2600839T (lt) 2018-03-26
IL223880A (en) 2017-01-31
PL2600839T3 (pl) 2018-07-31
KR101828768B1 (ko) 2018-02-13
WO2012016699A8 (en) 2013-02-07
AU2011287956A1 (en) 2013-01-10
RS57027B1 (sr) 2018-05-31
AU2011287956A8 (en) 2014-09-25
JP5792300B2 (ja) 2015-10-07
AU2011287956B2 (en) 2015-01-22
WO2012016699A2 (en) 2012-02-09
HUE035543T2 (en) 2018-05-28
CO6640315A2 (es) 2013-03-22
CA2804878C (en) 2019-01-08
CL2012003582A1 (es) 2013-06-07
NZ604735A (en) 2014-08-29
KR20130135238A (ko) 2013-12-10
BR112013002714A2 (pt) 2017-05-30
HRP20180143T1 (hr) 2018-02-23
CY1119887T1 (el) 2018-06-27
DK2600839T3 (da) 2018-01-29
MX2013001114A (es) 2013-03-12
ES2665344T3 (es) 2018-04-25
JP2013532698A (ja) 2013-08-19
ZA201300038B (en) 2013-09-25
PT2600839T (pt) 2018-04-17
CN103179953A (zh) 2013-06-26
WO2012016699A3 (en) 2012-08-16
RU2582390C2 (ru) 2016-04-27
EP2600839A2 (en) 2013-06-12
EP2600839B1 (en) 2018-01-10

Similar Documents

Publication Publication Date Title
PE20131108A1 (es) Forma de dosificacion farmaceutica que comprende 6'-fluoro-(n-metil- o n,n-dimetil)-4-fenil-4',9'-dihidro-3'h-espiro[ciclohexan-1,1'-pirano[3,4,b]indol]-4-amina
PE20131084A1 (es) Forma de dosificacion farmaceutica que comprende 6'-fluoro-(n-metil- o n,n-dimetil)-4-fenil-4',9'-dihidro-3'h-espiro[ciclohexan-1,1'-pirano[3,4,b]indol]-4-amina para el tratamiento de dolor nociceptivo
PE20142353A1 (es) Ansolvatos de sal de noribogaina
ECSP14012527A (es) Composiciones enriquecidas con dpa de ácidos grasos omega 3 poliinsaturados en forma de ácido libre
CO6571900A2 (es) Composiciones famaceúticas del compuesto espiro-oxindol para adminsitración tópica y sus usos como agentes terapeúticos
CU24350B1 (es) DERIVADOS DE 5-HETEROARIL-4-FENIL-4,5-DIHIDROPIRROLO(3,4-c)PIRAZOL-6-ONA ACTIVOS COMO INHIBIDORES DE BET
RU2013109138A (ru) ЛЕКАРСТВЕННАЯ ДОЗИРОВАННАЯ ФОРМА, КОТОРАЯ СОДЕРЖИТ 6'-ФТОР-(N-МЕТИЛ-ИЛИ N,N-ДИМЕТИЛ-)-4-ФЕНИЛ-4',9'-ДИГИДРО-3'Н-СПИРО[ЦИКЛОГЕКСАН-1,1'-ПИРАНО[3,4,b]ИНДОЛ]-4-АМИН
NZ591810A (en) Pharmaceutical compositions and related methods of delivery the composition comprises a medium chain fatty acid
NI201400003A (es) Una nueva composición terapéutica que contiene apomorfina como ingrediente activo
PE20140255A1 (es) Tableta dispersable en forma oral
EA201690005A1 (ru) Состав с модифицированной кинетикой высвобождения
CO6640318A2 (es) Formas de dosificación oral de bendamustina
PE20141113A1 (es) 1-piperazino-3-fenil-indanos deuterados para el tratamiento de esquizofrenia
PE20131107A1 (es) Forma de dosificacion farmaceutica que comprende 6'-fluoro-(n-metil- o n,n-dimetil)-4-fenil-4-fenil-4',9'-dihidro-3'h-espiro[ciclohexan-1,1'-pirano[3,4,b]indol]-4-amina
EA201390950A1 (ru) Гомогенные фармацевтические пероральные лекарственные формы, содержащие лерканидипин и эналаприл или их фармацетически приемлемые соли совместно с органической кислотой
PE20061390A1 (es) Formulaciones de acido hidroxamico suberoilanilida y procedimientos para la produccion de las mismas
PE20142444A1 (es) Nueva composicion de alfentanilo para el tratamiento del dolor agudo
UA109544C2 (uk) Фармацевтична композиція, що містить парацетамол, та спосіб її виготовлення
AR088845A1 (es) Composiciones farmaceuticas que contienen 7-(1h-imidazol-4-ilmetil)-5,6,7,8-tetrahidro-quinolina para el tratamiento de las enfermedades y las afecciones de la piel
EA201170583A1 (ru) Новая композиция для лечения эссенциальной тромбоцитемии
NI201200196A (es) Agentes terapéuticos 976
AR093275A1 (es) Una composicion farmaceutica soluble en agua que comprende al menos una sustancia terapeuticamente activa de caracteristicas hidrofobicas y al menos un compuesto seleccionado entre los sialoglicoesfingolipidos, los glicoesfingolipidos o una mezcla de sialoglicoesfingolipidos y glicoesfingolipidos
EA201100682A1 (ru) Стабильная фармацевтическая композиция, содержащая прегабалин, капсула, ее содержащая, способ получения и применение
MX359106B (es) Composicion farmaceutica inyectable de dexketoprofeno y tramadol.
EA201491404A1 (ru) Системные лекарственные формы с контролируемым высвобождением и улучшенной стабильностью

Legal Events

Date Code Title Description
FG Grant, registration